Quest Diagnostics INC: insider trades · United States · SEC (Form 4)

About Quest Diagnostics INC

Quest Diagnostics Incorporated (NYSE: DGX) is a leading U.S. diagnostic information services company headquartered in Secaucus, New Jersey, and listed on the NYSE in the United States. The company operates a broad clinical laboratory network and a large patient-access footprint, serving physicians, hospitals, health plans, employers, and consumers. Its model is centered on turning laboratory testing into actionable clinical information, combining test execution, logistics, digital ordering, and results delivery across a wide range of medical specialties. ([questdiagnostics.com](https://www.questdiagnostics.com/our-company/about-us?utm_source=openai)) Founded in 1967, Quest Diagnostics grew through decades of consolidation in the U.S. laboratory-services market and has established itself as one of the country’s benchmark diagnostic platforms. The company describes itself as the world’s leading provider of diagnostic information services, and its scale is notable: it says it serves about one in three adult Americans each year and roughly half of U.S. physicians and hospitals. That reach gives Quest meaningful operating leverage, a strong brand in routine and specialized testing, and a durable position in the care pathway. ([questdiagnostics.com](https://www.questdiagnostics.com/our-company/about-us?utm_source=openai)) Quest’s core business lines include routine blood chemistry, hematology, pathology, women’s health, infectious disease testing, oncology, genetics, and other specialty diagnostics. In addition to serving independent clinicians and health systems, it supports large enterprise customers through health-plan, employer, and consumer channels, as well as collaborative lab models with hospitals and integrated delivery networks. This mix provides a balance between high-volume commodity testing and higher-complexity specialty services, which is important in a sector where pricing pressure is offset by scale, workflow integration, and clinical relevance. ([questdiagnostics.com](https://www.questdiagnostics.com/our-company/about-us?utm_source=openai)) From a competitive standpoint, Quest is one of the major national players in U.S. diagnostics. Its advantages are scale, geographic coverage, broad test menus, logistics capabilities, and the ability to integrate acquisitions and strategic partnerships. The company has also emphasized digital and operational transformation, including collaborations designed to improve order-to-cash workflows and customer experience. Management’s messaging in 2025 and 2026 points to a strategy focused on sustainable growth, disciplined capital allocation, and deeper integration with healthcare providers and consumer health platforms. ([ir.questdiagnostics.com](https://ir.questdiagnostics.com/press-releases/press-release-details/2025/Quest-Diagnostics-to-Highlight-Strategic-Priorities-to-Drive-Sustainable-Growth-and-Deliver-Long-term-Shareholder-Value-at-2025-Investor-Day/default.aspx?utm_source=openai)) Recent developments reinforce that positioning. In February 2026, Quest reported strong fourth-quarter and full-year 2025 results, raised its 2026 guidance, and increased its quarterly dividend. In August 2025, it completed the acquisition of select clinical testing assets from Fresenius Medical Care’s Spectra Laboratories, strengthening its renal-testing franchise and related dialysis-service exposure. In April 2026, the company again posted revenue and earnings growth for the first quarter, indicating continued demand for its diagnostic services in the U.S. market. ([ir.questdiagnostics.com](https://ir.questdiagnostics.com/press-releases/press-release-details/2026/Quest-Diagnostics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results--Provides-Guidance-for-Full-Year-2026-Increases-Quarterly-Dividend-7-5-to-0-86-Per-Share/default.aspx?utm_source=openai))